StockData
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd (TLSA) company profile

TLSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 1, 2026Score 3/30
$0.58+0.01 (+1.75%)

Close on Nov 16, 2026Market cap $69.89MP/E –Yield –

About Tiziana Life Sciences

Pharmaceutical Preparations, SIC 2834

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing therapies for oncology and immune-mediated diseases with high unmet medical need. The company concentrates on developing novel drug candidates, primarily monoclonal antibodies targeting immune pathways. Its lead product candidate is Foralumab, which is being investigated across various indications including non-active secondary progressive multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. Additionally, its pipeline includes TZLS-501, an anti-IL6R monoclonal antibody. The company aims to provide treatments for patient populations suffering from neurodegenerative and inflammatory conditions.

The company operates internationally with corporate headquarters situated in Hamilton, Bermuda. Its principal executive offices are located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. In addition to its Bermuda headquarters, Tiziana maintains key executive and contact offices in London, United Kingdom, and conducts operations through subsidiaries spanning Bermuda, the United Kingdom, and the United States.

Summary of the business section of Tiziana Life Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Tiziana Life Sciences Ltd
Headquarters
London, England, X0
Address
3rd Floor, 11-12 St. James'S Square SW1Y 4LB
Phone
0044(0) 207-495-2379
Employees
10, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
D0
Fiscal year ends
December 31
Auditor
PKF Littlejohn LLP, London, England

Stock & identifiers

Ticker
TLSA
Exchange
Nasdaq
IPO date
Nov 21, 2018
Shares outstanding
121M, Dec 31, 2025
Filer category
Non-accelerated filer
Stock splits
2-for-1, Oct 29, 2019
SEC CIK
1723069
FIGI
BBG0129Q42X2
Share class FIGI
BBG0129Q42Y1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ivor ElrifiChief Executive Officer9,648,945
Keeren Rameshchandra ShahCHIEF OPERATING & FIN. OFFICER2,500
Gabriele M. CerroneDirector89,469,417

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 21, 2018
Offer price
$9.90
Securities offered
442,910
Gross proceeds
$4.38M
Exchange
Nasdaq
First trading day
Nov 20, 2018
First-day close
$8.35-15.7%
Lock-up ends (est.)
May 19, 2019

“Our ADSs have been approved for trading on the Nasdaq Global Market or Nasdaq, under the symbol “TLSA.” The initial public offering price is $9.90 per ADS, Our ordinary shares trade on AIM, a market of the London Stock Exchange plc, or London Stock Exchange, under the symbol “TILS.” On November 19, 2018, the last reported sale price of our ordinary shares was £0.795 per share (equivalent to $10.21 p”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“had 10 full time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 30, 2026Late filingNotification of late filing
Apr 30, 2025Late filingNotification of late filing
Apr 30, 2024Late filingNotification of late filing
Apr 29, 2022Late filingNotification of late filing
Oct 21, 2021Name changeName changed from Tiziana Life Sciences plc to Tiziana Life Sciences Ltd
Oct 20, 2021DelistingNotice of delisting from exchange (Form 25)
Apr 30, 2021Late filingNotification of late filing
Jun 15, 2020Late filingNotification of late filing
Nov 21, 2018IPOInitial public offering priced (424B4 prospectus)
Oct 30, 2018ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?